多西他赛治疗失败后的去势抵抗性前列腺癌及其骨转移治疗进展

Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure

去势抵抗性前列腺癌(CRPC)的标准治疗目前以多西他赛为化疗基础,但是对于多西他赛治疗失败后的CRPC尚缺乏有效的治疗手段。近年来,一些新的治疗药物已被批准用于临床治疗,还有一些药物则已经进入临床Ⅱ期或Ⅲ期试验,这些药物的作用机制包括稳定微管蛋白、抑制雄激素合成、阻断雄激素受体、骨靶向、调节免疫功能等。本文综述多西他赛治疗失败后的CRPC的治疗新选择。

The standard first-line treatment of castration-resistant prostate cancer （CRPC） is docetaxel-based chemotherapy. However, cRPC may not respond to docetaxel due to drug resistance or other causes. Several new therapeutic agents have been developed, some of which are approved by FDA or on clinical trials. The mechanisms of action of these agents include stabilizing microtubules, inhibiting hormone synthesis, blocking androgen receptor, bone targeting this article we review the novel therapeutic options for CPRC or immune regulation. In after docetaxel failure